ClinicalTrials.gg
RecruitingNCT06197048Updated Jan 9, 2024

Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder

An interventional study of Nutritional counseling in Cardiovascular Diseases, Schizophrenia and Psychosis, sponsored by Vestre Viken Hospital Trust. Recruiting at 2 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-09.

Sponsored by Vestre Viken Hospital Trust · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Sep 2023, registered Dec 2023).
  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to compare the effect of nutritional counseling versus no treatment in patients with schizophenia or bipolar affective disorder.

The main question it aims to answer are:

  • Can nutritional counseling have a preventive effect on the development of cardiovascular disease in patients with schizophenia or bipolar affective disorder?

Participants will meet a nutritionist at baseline to asess nutritional status, biochemical and anthropometric measurements. Then, half of the study population will receive nutritional counseling. After six weeks, the same baseline measurements will be repeated to examine any potential differences between the two groups. After the intervention, the control group will be offered the same counseling as the intervention group received during the study.

Read the detailed description

People with severe mental illness have a shorter life expectancy compared to the general population. Individuals with schizophrenia or bipolar affective disorder have an estimated reduce life expectancy by an average of 10-20 years. Increased mortality is caused by many factors, but cardiovascular diseases contributes the most. Increased prevalence of cardiovascular disease is mainly due to a poor lifestyle, which includes smoking, physical inactivity and an unhealthy diet.

It is important to find treatment that can provide better quality of life and longer life expectancy in these patient groups. Few clinical studies have been conducted on the effect of nutritional counseling on biochemical and anthropometric measurements related to cardiovascular diseases. Therefore, we want to investigate this through a randomized controlled trial.

02

Conditions studied

  • Cardiovascular Diseases
  • Schizophrenia
  • Psychosis
  • Bipolar Disorder

Keywords

  • Severe mental disorders
  • Nutritional counseling
  • Cardiovascular disease
  • Schizophrenia
  • Bipolar affective disorder
  • Randomzied controlled trial
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 40 is below the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Vestre Viken Hospital Trust is the lead sponsor of 52 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 18 years
  • Diagnosed with either schizophrenia/psychosis or bipolar affective disorder
  • Patients treatet in Vestre Viken healthcare company, at either Asker district psychiatric center or Blakstad hospital

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Interventions

  • BehavioralNutritional counseling

    The intervention group will recieve 30 x 2 minutes with nutritonal counseling seperatet by a 15 minutes break. The participants will receive individually tailored guidance based on the information recieved at baseline measurments. The couseling will be based on the Norwegian goverments dietary advices and the recommendation from the Directorate of Health for the prevention of cardiovascular diseases.

06

What researchers measure

Primary outcomes

  1. Non-HDL cholesterol

    HDL-cholesterol - total cholesterol, biochemical test

    Time frame: 6 weeks

Secondary outcomes

  1. total cholesterol

    biochemical test

    Time frame: 6 weeks

  2. HDL-cholesterol

    biochemical test

    Time frame: 6 weeks

  3. Triglycerids

    biochemical test

    Time frame: 6 weeks

  4. HbA1c

    biochemical test

    Time frame: 6 weeks

  5. ALT AST/ALT AST/ALT

    biochemical test

    Time frame: 6 weeks

  6. fasting glucose

    biochemical test

    Time frame: 6 weeks

  7. Vitamin D

    biochemical test

    Time frame: 6 weeks

  8. Folate

    biochemical test

    Time frame: 6 weeks

  9. LDL-cholesterol

    biochemical test

    Time frame: 6 weeks

  10. Weight

    anthropometric measurement

    Time frame: 6 weeks

  11. waist circumference

    anthropometric measurement

    Time frame: 6 weeks

  12. Bloodpressure

    Time frame: 6 weeks

  13. 24-hour dietary recall

    interview

    Time frame: 6 weeks

  14. Food frequency questionnaire

    questionnaire

    Time frame: 6 weeks

07

Study locations

2 of 2 sites recruiting
  • Vestre Viken Health Trust
    Drammen, Viken 3004, Norway
    Recruiting
  • Department of Research and Delvelopment, Mental health and Addiction, Vestre Viken Hospital Trust
    Drammen, 3004, Norway
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — The IPD will be stored at TSD- services for sensitive data. Only researchers in this prosject will have acsess

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for May 2024, 7 months after the start.

Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 7 months is below that.

Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2023
First posted
Jan 9, 2024
StartActual
Sep 25, 2023
Primary completionEst.
May 15, 2024
CompletionEst.
Dec 1, 2028
Last update
Jan 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06197048
Lead sponsor
Vestre Viken Hospital Trust
Collaborators
University of Oslo
Responsible party
Sponsor
First posted
Jan 9, 2024
Start date
Sep 25, 2023
Primary completion
May 15, 2024 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Jan 9, 2024

Study contacts

Dawn E Peleikis, phD
Contact
dawn.peleikis@vestreviken.no
+4799405812
Camilla N Myrdal, Master
Contact
camilla.myrdal@studmed.uio.no
+4794814040

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion